natgillin/translations-raw huggingface dataset:
This is then followed by the standard 75-mg dose once a day for at least four weeks (in ‘ST segment elevation’ myocardial infarction) or for up to 12 months (in unstable angina or ‘non-Q-wave’ myocardial infarction).
Temu sledi običajni 75-miligramski odmerek enkrat na dan v trajanju najmanj štirih tednov (pri miokardnem infarktu z dvigom spojnice ST) ali največ 12 mesecev (pri nestabilni angini pektoris ali pri miokardnem infarktu brez zobca Q).
This is then followed by the standard 75-mg dose once a day for at least four weeks (in ‘ST segment elevation’ myocardial infarction) or for up to 12 months (in unstable angina or ‘non-Q-wave’ myocardial infarction).
Temu sledi običajni 75–miligramski odmerek enkrat na dan v trajanju najmanj štirih tednov (pri miokardnem infarktu z dvigom spojnice ST) ali največ 12 mesecev (pri nestabilni angini pektoris ali pri miokardnem infarktu brez zobca Q).
This is then followed by the standard 75-mg dose once a day for at least four weeks (in ‘ST-segment-elevation’ myocardial infarction) or for up to 12 months (in unstable angina or ‘non-Q-wave’ myocardial infarction).
Temu sledi običajni 75-miligramski odmerek enkrat na dan v trajanju najmanj štirih tednov (pri miokardnem infarktu z dvigom spojnice ST) ali največ 12 mesecev (pri nestabilni angini pektoris ali miokardnem infarktu brez zobca Q).
This is then given into a vein either as a ‘bolus’ injection (given all at once) or as an infusion after being diluted.
Ta se nato da v veno kot „bolusna“ injekcija (bolnik prejme celo injekcijo naenkrat) ali kot infuzija po razredčenju.
This is thought to be the result of licking the application site straight after treatment.
Do tega naj bi prišlo, če žival takoj po nanosu poliže mesto nanosa.
This is thought to lead to increases in the levels of dopamine and noradrenaline between nerve cells in the areas of the brain that are involved in the control of mood.
Domneva se, da se s tem povečajo ravni dopamina in noradrenalina med živčnimi celicami v delu možganov, ki sodeluje pri nadzoru razpoloženja.
This is to avoid postural hypotension (a fall in blood pressure on standing up).
To je potrebno, da bi se izognili posturalni hipotenzji (padcu krvenga tlaka pri vstajanju);
This is to be expected as the therapeutic principle of photodynamic therapy is based on phototoxic effects of protoporphyrin IX which is synthesized from the active ingredient 5- aminolaevulinic acid.
To je pričakovano, saj terapevtsko načelo fotodinamičnega zdravljenja temelji na fototoksičnih učinkih protoporfirina IX, ki se sintetizira iz zdravilne učinkovine 5-aminolevulinske kisline.
This is to help limit flu-like symptoms.
To pomaga pri blaženju gripi podobnih simptomov.
This is to help you get pregnant.
S tem se vam pomaga zanositi.
This is to limit flu-like symptoms which some people experience when they start using Avonex.
To pomaga pri blaženju gripi podobnih simptomov, ki se pojavijo pri nekaterih bolnikih ob začetku uporabe zdravila Avonex.
This is to make sure that the fungal infection has gone.
Le tako zagotovimo, da bo glivična okuţba odpravljena.
This is to prevent your symptoms from coming back again or becoming worse.
Tako bo preprečil, da bi se vaši simptomi spet pojavili ali poslabšali.
This is to reduce the risk of injection site reactions.
S tem zmanjšate tveganje za reakcije na mestu injiciranja.
This is to try to identify those patients who are more likely to respond to treatment.
Tako bo poskušala opredeliti bolnike, pri katerih obstaja večja verjetnost odziva na zdravljenje.
This is used in exactly the same way.Use of purple
Ta se uporablja povsem enako.
This is usually achieved within a month.
To stanje je običajno doseženo v roku enega meseca.
This is usually reversible and appears to be dose- dependent.
Ta je navadno reverzibilna in kaže, da je odvisna od odmerka.
This is usually reversible if 6–mercaptopurine therapy is stopped soon enough but fatal liver damage has occurred.
Ta je običajno reverzibilna, če se zdravljenje s 6-merkaptopurinom prekine dovolj zgodaj, vendar pa že pride do jetrne okvare s smrtnim izidom.
This is usually worst with the first morning dose and disappears after the first days of treatment.
Navadno so težave najhujše pri prvem jutranjem odmerku in po prvih dneh zdravljenja izzvenijo.
This is very common in severe chronic neutropenia patients, common in HIV patients and uncommon in normal stem cell donors. if you are being treated for severe chronic neutropenia and you have blood in your urine (haematuria).
To je zelo pogosto pri bolnikih s hudo kronično nevtropenijo, pogosto pri bolnikih s HIV in občasno pri zdravih dajalcih matičnih celic. če se zdravite zaradi hude kronične nevtropenije in imate kri v urinu (hematurija).
This is what causes the symptoms of MS.
To povzroča simptome MS.
This is when you and your doctor agree that the symptoms are adequately controlled and the side effects of the medicines are acceptable.
To je takrat, ko se vi in vaš zdravnik strinjata, da so simptomi ustrezno nadzorovani in neželeni učinki zdravil sprejemljivi.
This is when your bones are more likely to break.
»osteoporoza«, zaradi katere se kosti lažje zlomijo.
This is why the vaccine suspension should only be prepared as and when required
Prav zato je treba suspenzijo cepiva pripraviti ko in kadar je potrebna.
This Ki value is far higher than the expected plasma levels of imatinib in patients, consequently no interaction is expected upon co- administration of either 5-fluorouracil or paclitaxel and imatinib.
Ta vrednost Ki je mnogo večja kot pričakovane plazemske koncentracije imatiniba pri bolnikih, zato po sočasnem dajanju bodisi 5-fluorouracila ali paklitaksela in imatiniba ni pričakovati medsebojnega delovanja.
This kind of ‘reassortment’ between H and N types happens naturally in the wild but in this case has been carried out in the laboratory to produce a virus with these very specific properties.
Ta vrsta »prerazporejanja« med tipoma H in N poteka v naravi spontano, v tem primeru pa je bila izvedena v laboratoriju z namenom, da bi izdelali virus s temi posebnimi lastnostmi.
This lack of oestrogen leads to a thinning of the tissues in and around the vagina and a reduction in the amount of mucus that keeps the vaginal environment moist.
To pomanjkanje estrogena povzroči tanjšanje tkiv v nožnici in okoli nje ter zmanjšanje količine sluzi, ki ohranja vlažnost nožničnega okolja.
This le afle t was last approve d in
Navodilo je bilo odobreno
This le afle t was last approved in
Navodilo je bilo odobreno
This le afle t was last revised in
Navodilo je bilo nazadnje revidirano dne
This leads to a reduction in the release of substances that are involved in the inflammation process, such as histamine, thereby helping to keep the airways clear and allowing the patient to breathe more easily.
To povzroči zmanjšano sproščanje snovi, ki sodelujejo v vnetnih procesih, na primer histamina, s tem pa pomaga ohranjati prehodnost dihalnih poti in bolniku omogoča lažje dihanje.
This leads to an increased production of platelets.
Zato začne nastajati večje število trombocitov.
This leads to changes in the activity of the brain, bringing about ‘delta’ (slow) brain waves and night-time sleep.
To povzroči spremembe aktivnosti možganov ter pospeši „delta“ (počasne) možganske valove in nočni spanec.
This leads to inhibition of cell growth, while showing significantly less activity against EGFR in wild- type cell lines (apparent IC50s from 480 nM to 1.8 μM against phospho-EGFR).
Tako zavre rast celic, bistveno manj pa deluje proti EGFR v celičnih linijah divjega tipa (navidezne IC50 proti fosfo-EGFR od 480 nM do 1,8 µM).
This leads to less bone loss in osteoporosis and less disease activity in Paget’s disease.
Zaradi tega je pri osteoporozi izguba kostne mase manjša, pri Pagetovi bolezni pa je bolezen manj aktivna.
This leads to less bone loss in osteoporosis and less disease activity in Paget’s disease.
Zaradi tega se pri osteoporozi zmanjša izguba kostne mase, pri Pagetovi bolezni pa dejavnost bolezni.
This leads to less bone loss in osteoporosis and less disease activity in Paget’s disease.
Zaradi tega se pri osteoporozi zmanjša izguba kostne mase, pri Pagetovi bolezni pa se zmanjša dejavnost bolezni.
This leads to less bone loss.
To zmanjša izgubo kostne mase.
This leads to less disease activity in Paget’s disease.
To povzroči, da je Pagetova bolezen manj dejavna.
This leads to opening of the chloride channels on the postsynaptic junction, the inflow of chloride ions and induction of an irreversible resting state.
Selektivno se veže na klorove ionske kanale v živčnih in mišičnih celicah parazitov, kar poveča prepustnost celične membrane prizadetih celic za klorove ione.
This leads to phosphate accumulating in the body, which, in the long term, can cause complications such as heart disease.
To vodi do kopičenja fosfatov v telesu, kar lahko dolgoročno povzroči zaplete, na primer bolezni srca.
This leads to reduced production and concentration of testosterone and other testicular steroids, including androstenone, one of the main substances responsible for boar taint.
To vodi do zmanjšanega nastajanja in koncentracije testosterona in drugih testikularnih steroidov, vključno z androstenonom, ene izmed glavnih spojin odgovornih za vonj po merjascu.
This leads to the tumour dying back and getting smaller, particularly when the medicine is combined with other cytotoxic (cell- killing) medicines and raised temperature.
To povzroči, da tumor odmira in se manjša, še zlasti takrat, kadar se zdravilo daje v kombinaciji z drugimi citotoksičnimi zdravili (zdravili za uničenje celic) in ob povišani temperaturi.
This leaflet has been written as though the person taking the medicine is reading it.
To navodilo je napisano, kot da ga bo brala oseba, ki jemlje zdravilo.
This leaflet has been written for the parent or carer who will give this medicine to the child- please read this information carefully.
To navodilo je napisano za starše ali negovalce, ki bodo zdravilo dajali otroku – navodilo natančno preberite
This leaflet has been written for the person taking the medicine.
V navodilu za uporabo so podana tudi obsežnejša navodila za injiciranje zdravila.
This leaflet is available in all EU/EEA languages on the European Medicines Agency website.
Navodilo za uporabo je na voljo v vseh jezikih EU/EGP na spletni strani Evropske agencije za zdravila.
This leaflet is available in all EU/EEA languages on the European Medicines Agency website.
To navodilo za uporabo je na voljo v vseh uradnih jezikih EU/EGP na spletni strani Evropke agencije za zdravila.
This leaflet was last approved
Navodilo je bilo odobreno
This leaflet was last approved in
Navodilo je bilo nazadnje revidirano dne MM/LLLL.
This leaflet was last approved in
Navodilo je bilo nazadnje revidirano dne:
This leaflet was last approved in
Navodilo je bilo odbreno
This leaflet was last approved in
Navodilo je bilo zadanje revidirano dne:
This leaflet was last approved in
Zadnja potrditev navodila za uporabo
This leaflet was last approved in
Zdravilo je bilo odobreno
This leaflet was last approved in .
Navodilo je bilo nazadnje revidirano dne }.
This leaflet was last approved in .
Navodilo je bilo odobreno
This leaflet was last approved in .
Navodilo je bilo odobreno ....
This leaflet was last approved in MM/YYYY
Navodilo je bilo nazadnje revidirano dne MM/YYY
This leaflet was last approved in MM/YYYY.
Navodilo je bilo nazadnje revidirano dne {MM/LLLL}
This leaflet was last approved in MM/YYYY.
Navodilo je bilo odobreno MM/LLLL.
This leaflet was last approved in MMM/YYYY
Navodilo je bilo odobreno {MM/LLLL}.
This leaflet was last approved in Other sources of information
Navodilo je bilo nazadnje revidirano Drugi viri informacij
This leaflet was last approved in Other sources of information
Navodilo je bilo odobreno Drugi viri informacij
This leaflet was last approved in {MM/YYYY}
Navodilo je bilo nazadnje revidirano dne {mesec LLLL}.
This leaflet was last approved in {MM/YYYY}
Navodilo je bilo odobreno:
This leaflet was last approved in {MM/YYYY}.
Navodilo je bilo nazadnje odobreno dne {MM/LLLL}
This leaflet was last approved in {MM/YYYY}.
Navodilo je bilo nazadnje revidirano dne MM/LLLL
This leaflet was last approved in {MM/YYYY}.
Navodilo je bilo odobreno (datum)
This leaflet was last approved in {MM/YYYY}.
Navodilo je bilo odobreno:
This leaflet was last approved in {MM/YYYY}.
Navodilo je bilo zadanje revidirano dne:
This leaflet was last approved in.
Navodilo je bilo odobreno (datum)
This leaflet was last approved in:
Navodilo je bilo nazadnje revidirano dne MM/LLLL
This leaflet was last approved on MM/YYYY
Navodilo je bilo odobreno
This leaflet was last approved on XXXXX
Navodilo je bilo odobreno XXXXX.
This leaflet was last approved on.
Navodilo je bilo odobreno
This leaflet was last approved.
Navodilo je bilo odobreno:
This leaflet was last last revised in <{MM/YYYY}> <{month YYYY}>
Navodilo je bilo nazadnje revidirano dne <{MM/LLLL}> <{mesec LLLL}>
This leaflet was last revised approved in Other sources of information
Navodilo je bilo revidirano Drugi viri informacij
This leaflet was last revised in
Datum zadnje revizije:
This leaflet was last revised in
Navodilo je bilo nazadne revidirano dne
This leaflet was last revised in
Navodilo je bilo nazadnje revidirano dne <{MM/LLLL}
This leaflet was last revised in
Navodilo je bilo nazadnje revidirano dne {MM/LLLL}
This leaflet was last revised in
Navodilo je bilo nazadnje revidirano dne: 05/2016
This leaflet was last revised in
Navodilo je bilo nazadnje revidirano xxxxx
This leaflet was last revised in
Navodilo je bilo nazadnje revidirano {MM/LLLL}
This leaflet was last revised in
Navodilo je bilo odobreno
This leaflet was last revised in (MM/YYYY).
Navodilo je bilo nazadnje revidirano {MM/LLLL}
This leaflet was last revised in .{MM/YYYY}.
Navodilo je bilo nazadnje revidirano dne
This leaflet was last revised in <MM/YYYY>
Navodilo je bilo nazadnje revidirano dne <MM/LLLL>
This leaflet was last revised in <MM/YYYY>
Navodilo je bilo nazadnje revidirano dne.
This leaflet was last revised in <MM/YYYY> <month YYYY>.
Navodilo je bilo nazadnje revidirano dne {MM/YYYY}
This leaflet was last revised in <Month YYYY>
Navodilo je bilo nazadnje revidirano
This leaflet was last revised in <month YYYY>
To navodilo je bilo nazadnje revidirano dne <mesec LLLL>
This leaflet was last revised in <{MM/YYYY}
Navodilo je bilo nazadnje revidirano dne <{MM/LLLL}
This leaflet was last revised in <{MM/YYYY}>
Navodilo je bilo nazadnje revidirano <{MM/LLLL}>
This leaflet was last revised in <{MM/YYYY}>
Navodilo je bilo nazadnje revidirano dne { MM/LLLL }
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}
Navodilo je bilo nazadnje revidirano <{MM/LLLL}> <{mesec LLLL}
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}.>
Navodilo je bilo nazadnje revidirano <{MM/LLLL}> <{mesec LLLL}.>
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}.>
Navodilo je bilo nazadnje revidirano dne
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}.>
Navodilo je bilo nazadnje revidirano dne <{MM/LLLL}> <{mesec LLLL}.>
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}.>
Navodilo je bilo odobreno {MM/LLLL}
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}>
Navodilo je bilo nazadnje revidirano dne <{MM/LLLL}> <{mesec LLLL}>
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}>.
Navodilo je bilo nazadnje revidirano dne <{MM/LLLL}> <{mesec LLLL}.>
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}>.
Navodilo je bilo nazadnje revidirano {MM/LLLL}
This leaflet was last revised in <{MM/YYYY}>: Other sources of information
Navodilo je bilo nazadnje revidirano dne {MM/LLLL} Drugi viri informacij
This leaflet was last revised in <{MM/YYYY}><{month YYYY}.>
Navodilo je bilo nazadnje revidirano dne <{MM/LLLL}> <{mesec LLLL}.>
This leaflet was last revised in <{MM/YYYY}><{month YYYY}>
Navodilo je bilo nazadnje revidirano dne <{MM/LLLL}><{mesec LLLL}>
This leaflet was last revised in <{MM/YYYY}><{month YYYY}>.
Navodilo je bilo nazadnje revidirane dne <{MM/LLLL}><{mesec LLLL}>.
This leaflet was last revised in <{MM/YYYY}><{month YYYY}>.
Navodilo je bilo nazadnje revidirano dne <{MM/LLLL}> <{mesec LLLL}>.
This leaflet was last revised in <{month YYYY}>.
Navodilo je bilo nazadnje revidirano <{mesec LLLL}>.
This leaflet was last revised in <{month YYYY}>.
Navodilo je bilo nazadnje revidirano dne <{mesec LLLL}>.
This leaflet was last revised in April/2014
Navodilo je bilo nazadnje revidirano dne {MM/LLLL}
This leaflet was last revised in JUNE/2016 Other sources of information
Navodilo je bilo nazadnje revidirano dne <{MM/LLLL}> Drugi viri informacij
This leaflet was last revised in MM/YYYY
Navodilo je bilo nazadnje revidirano
This leaflet was last revised in MM/YYYY
Navodilo je bilo nazadnje revidirano dne Drugi viri informacij
This leaflet was last revised in MM/YYYY Other sourses of information
Navodilo je bilo nazadnje revidirano dne MM/LLLL Drugi viri informacij
This leaflet was last revised in MM/YYYY.
Navodilo je bilo nazadnje revidirano {MM/LLLL}
This leaflet was last revised in MM/YYYY.
Navodilo je bilo odobreno
This leaflet was last revised in MM/YYYY}
Navodilo je bilo nazadnje revidirano dne MM/LLLL
This leaflet was last revised in MMM/YYYY.
Navodilo je bilo revidirano dne.
This leaflet was last revised in Month YYYY Other sources of information
Navodilo je bilo nazadnje revidirano dne mesec LLLL Drugi viri informacij
This leaflet was last revised in Month YYYY Other sources of information
Navodilo je bilo nazadnje revidirano mesec LLLL Drugi viri informacij
This leaflet was last revised in Other source of information
Navodilo je bilo nazadnje revidirano Drugi viri informacij
This leaflet was last revised in Other sources of information
Drugi viri informacij
This leaflet was last revised in Other sources of information
Navodilo je bilo nazadnje revidirano dne Drugi viri infomacij
This leaflet was last revised in Other sources of information
Navodilo je bilo nazadnje revidirano: Drugi viri informacij
This leaflet was last revised in Other sources of information
Navodilo je bilo odobreno
This leaflet was last revised in Other sources of information
Navodilo je bilo revidirano Drugi viri informacij
This leaflet was last revised in Other sources of information:
Navodilo je bilo nazadnje revidirano Drugi viri informacij:
This leaflet was last revised in XX/XXX.
Navodilo je bilo nazadnje revidirano dne XX/XXXX.
This leaflet was last revised in xxx
Navodilo je bilo nazadnje revidirano dne xxx.
This leaflet was last revised in xxxxxx
Navodilo je bilo nazadnje revidirano xxxxx
This leaflet was last revised in {08/2016} Other sources of information
Navodilo je bilo nazadnje revidirano dne {08/2016} Drugi viri informacij
This leaflet was last revised in {date}
Navodilo je bilo nazadnje revidirano dne {datum}
This leaflet was last revised in {date}
Navodilo je bilo odobreno {datum}
This leaflet was last revised in {date}.
Navodilo je bilo nazadnje revidirano { MM/LLLL }
This leaflet was last revised in {MM/2016}.
Navodilo je bilo nazadnje revidirano {MM/2016}.
This leaflet was last revised in {MM/YYYY}
Navodilo je bilo nazadnje revidirano dne (MM/LLLL)
This leaflet was last revised in {MM/YYYY}
Navodilo je bilo nazadnje revidirano dne MM/LLLL
This leaflet was last revised in {MM/YYYY}
Navodilo je bilo nazadnje revidirano dne {MM.
This leaflet was last revised in {MM/YYYY}
Navodilo je bilo nazadnje revidirano dne:
This leaflet was last revised in {MM/YYYY} Other sources of information
Navodilo je bilo nazadnje revidirano dne Drugi viri informacij
This leaflet was last revised in {MM/YYYY} Other sources of information
Navodilo je bilo nazadnje revidirano Drugi viri informacij
This leaflet was last revised in {MM/YYYY}.
Navodilo je bilo nazadnje odobreno
This leaflet was last revised in {MM/YYYY}.
Navodilo je bilo nazadnje pregledano
This leaflet was last revised in {MM/YYYY}.
Navodilo je bilo nazadnje revidirano dne MM/LLLL Drugi viri informacij
This leaflet was last revised in {MM/YYYY}.
Navodilo je bilo nazadnje revidirano dne MM/LLLL.
This leaflet was last revised in {MM/YYYY}.
Navodilo je bilo nazadnje revidirano dne MM/LLLL.
This leaflet was last revised in {MM/YYYY}.
Navodilo je bilo nazadnje revidirano dne{MM/LLLL}.
This leaflet was last revised in {MM/YYYY}.
Navodilo je bilo nazadnje revidirano mesec LLLL
This leaflet was last revised in {MM/YYYY}.
Navodilo je bilo nazadnje revidirano { MM/LLLL }
This leaflet was last revised in {MM/YYYY}.
Opozorila so navedena v navodilu za uporabo.
This leaflet was last revised in {MM/YYYY}.
Ta učinek se je pokazal v
This leaflet was last revised in {mmm YYYY}
Navodilo je bilo nazadnje revidirano {MM/LLLL}
This leaflet was last revised in {month XXXX}
Navodilo je bilo nazadnje revidirano v {mesec LLLL}
This leaflet was last revised in {month YYYY} Other sources of information
Navodilo je bilo nazadnje revidirano dne Drugi viri informacij
This leaflet was last revised in {month/YYYY}.
Navodilo je bilo nazadnje revidirano dne {mesec/LLLL}
This leaflet was last revised in {month/YYYY}.
Navodilo je bilo nazadnje revidirano v {MM/LLLL}
This leaflet was last revised in {month/YYYY}.
Navodilo je bilo nazadnje revidirano {mesec LLLL}
This leaflet was last revised in MM/YYYY.
Navodilo je bilo nazadnje revidirano dne:
This leaflet was last revised in:
Navodilo je bilo nazadnje revidirano dne.
This leaflet was last revised in: .
Navodilo je bilo nazadnje revidirano dne.
This leaflet was last revised in: <Month YYYY>
Navodilo je bilo nazadnje revidirano dne <mesec/LLLL>
This leaflet was last revised in: Other source of information
Navodilo je bilo nazadnje revidirano dne: Drugi viri informacij
This leaflet was last revised in: Other sources of information
Navodilo je bilo nazadnje revidirano dne Drugi viri informacij
This leaflet was last revised in{ MM/YYYY}.
Navodilo je bilo nazadnje revidirano dne {MM/LLLL}
This leaflet was last revised in{MM/YYYY} Other sources of information
Navodilo je bilo nazadnje revidirano dne {MM/LLLL} Drugi viri informacij
This leaflet was last revised on Other sources of information
Navodilo je bilo nazadnje revidirano dne Drugi viri informacij
This leaflet was last revised on {MM/YYYY}
Navodilo je bilo nazadnje revidirano {MM/LLLL}
This leaflet was last revised Other sources of information
Navodilo je bilo nazadnje revidirano Drugi viri informacij
This leaflet was last revisedin Other sources of information
Navodilo je bilo nazadnje revidirano dne
This leaflet was last revisedin Other sources of information
Navodilo je bilo nazadnje revidirano dne Drugi viri informacij
This leaflet was lastrevised in
Navodilo je bilo nazadnje revidirano
This leafletwas last revised in {MM/YYYY}
Navodilo je bilo nazadnje revidirano dne {MM/LLLL}
This led to a decrease in the effectiveness of the medicine.
Zaradi tega je bilo zdravilo manj učinkovito.
This lets the empty syringe move up until the whole needle is covered by the needle guard (Figure 7).
Na ta način se bo prazna injekcijska brizga pomaknila navzgor dokler ne bo celotna igla pokrita z varovalom za iglo (slika 7).
This lets the powder in the capsule be released when you breathe in.
To omogoči izhajanje praška iz kapsule med vdihom.
This LH/CG transmembrane receptor is a member of the super-family of G protein- coupled receptors; specifically, it has a large extra-cellular domain.
Ta LH/CG transmembranski receptor sodi v super- družino receptorjev z G proteini, za katere je značilen velik ekstracelularni del.
This limits nerve damage caused by MS.
To omeji obseg poškodb živcev, do katerih pride zaradi multiple skleroze.
This lower dose is recommended for patients who cannot tolerate the higher dose
Ta nižji odmerek se priporoča za bolnike, ki ne morejo prenašati višjih odmerkov.
This lowers the heart’s need for oxygen especially in the situations when an angina attack is more likely to happen.
Tako zmanjšuje potrebo srca po kisiku, zlasti v položajih, ko so anginozni napadi verjetnejši.
This magnitude of reduction was observed within 4 weeks of treatment.
Tolikšno zmanjšanje so ugotovili v 4-ih tednih zdravljenja.
This makes a total of three weeks with the patches.
To so skupaj trije tedni uporabe obliža